Cyclerion Therapeutics: Clinical Trials

6 trials sponsored by Cyclerion Therapeutics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated. 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 26Completed 5, Terminated 1

Follow Cyclerion Therapeutics: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
IW-1701, Placebo - Sickle Cell Disease
Phase 2CompletedCyclerion Therapeutics882017-12-222023-07-21
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
IW-1973, Placebo Oral Tablet - Heart Failure With Preserved Ejection Fraction
Phase 2CompletedAkebia Therapeutics1962017-11-072022-09-15
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
IW-1973, Placebo - Type 2 Diabetes Mellitus With Diabetic Nephropathy
Phase 2CompletedAkebia Therapeutics1562017-08-012022-09-15
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
Olinciguat, Matching Placebo - Achalasia
Phase 2TerminatedCyclerion Therapeutics92017-04-062021-05-04
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
IW-1973, Placebo - Diabetes Mellitus, Type 2, Hypertension
Phase 2CompletedCyclerion Therapeutics262017-02-282020-08-31
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
Matching Placebo, IW-1973 - Diabetes Mellitus, Type 2, Hypertension
Phase 2CompletedCyclerion Therapeutics112016-09-012020-04-16

Conditions studied

Diabetes Mellitus, Type 2 (2)  ·  Hypertension (2)  ·  Anemia, Sickle Cell (1)  ·  Esophageal Achalasia (1)  ·  Heart Failure (1)

Interventions

praliciguat (4)

Countries

United States (6)  ·  Canada (1)  ·  Lebanon (1)  ·  United Kingdom (1)

Top investigators

Jelena Seferovic, MD PhD (1)  ·  John Hanrahan, MD MPH (1)

Results publications

PMID 31858186, PMID 32105984, PMID 33079154, PMID 33328269, PMID 39833553